維亞生物(01873.HK)預期年度將扭虧為盈
格隆匯3月13日丨維亞生物(01873.HK)公吿,與上年度的淨虧損人民幣99.8百萬元及2023財年的股東應占淨虧損人民幣116.1百萬元相比,集團預期截至2024年12月31日止年度將錄得扭虧為盈,淨利潤介於人民幣210百萬元至人民幣240百萬元,股東應占淨利潤介於人民幣150百萬元至人民幣180百萬元。
集團預期本年度經調整非國際財務報吿準則淨利潤及股東應占淨利潤(經扣除一次性重組開支、物業、廠房及設備減值虧損、附屬公司股份獎勵開支及收購資產攤銷)將分別介於人民幣300百萬元至人民幣330百萬元及人民幣240百萬元至人民幣270百萬元。該增長主要歸因於合同研究組織(CRO)業務於本年度下半年恢復增長、營運效率提升令經營利潤率上升以及集團於本年度內收到里程碑付款確認投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.